Temozolomide is currently only approved by the FDA for patients with glioblastoma multiforme (GBM) or anaplastic astrocytoma, but response to temozolomide is associated with MGMT deficiency and a functional DNA MMR pathway in several different cancer types (3–6). This evidence concerns the gene MGMT and glioblastoma.